From the Research
Time to Symptom Improvement with Fidaxomicin
- The time to symptom improvement with fidaxomicin for diarrhea in C. difficile infection is not explicitly stated in the provided studies 1, 2, 3, 4, 5.
- However, the studies report the response rates and recurrence rates of fidaxomicin treatment for C. difficile infection:
- A study published in 2018 found that response occurred in 90% of patients, with responders having fewer prior CDI episodes than nonresponders 1.
- A study published in 2023 found that fidaxomicin led to resolution of C. difficile infection in 60.6% of patients with inflammatory bowel disease, with a median time to recurrence of 55 days 2.
- Another study published in 2015 reported a clinical success rate of 96.7% with fidaxomicin treatment, with 10.3% of patients experiencing recurrence within 90 days 4.
- The studies suggest that fidaxomicin is an effective treatment for C. difficile infection, with high response rates and low recurrence rates 1, 2, 4, 5.
- Fidaxomicin has a favorable pharmacological profile, including a narrow spectrum of activity, minimal impact on normal faecal microflora, and attainment of very high faecal concentrations 3, 5.